Citadel Advisors
AEON.WS

Citadel Advisors’s AEON Biopharma Inc AEON.WS Stock Holding History

Citadel Advisors’s Portfolio AEON.WS Stock Details AEON.WS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-59,281
Closed -$2.7K – 15779
2022
Q4 		$2.7K Sell
59,281
-58,683
-50% -$2.37K ﹤0.01% 14296
2022
Q3 		$8K Sell
117,964
-2,622
-2% -$239 ﹤0.01% 12318
2022
Q2 		$18K Sell
120,586
-173,015
-59% -$36.4K ﹤0.01% 12444
2022
Q1 		$88K Sell
293,601
-46,618
-14% -$19.2K ﹤0.01% 12401
2021
Q4 		$173K Sell
340,219
-20,916
-6% -$11.6K ﹤0.01% 12071
2021
Q3 		$198K Buy
361,135
+163,217
+82% +$120K ﹤0.01% 11997
2021
Q2 		$200K Buy
+197,918
New +$150K ﹤0.01% 12165

Other funds holding AEON.WS

LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
AC
Athos Capital Hong Kong $324M AUM 16.62% 1-Year Est. Return
SCM
Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Citadel Advisors's AEON.WS Position: Q1 2023 in Review

Citadel Advisors sold out of AEON Biopharma Inc (AEON.WS) in Q1 2023, closing a stake of 59,281 shares — an estimated $2.7K sold.

Citadel Advisors first reported a position in AEON.WS in Q2 2021 and held it in 7 quarters. The position peaked at $200K in Q2 2021. 49 funds tracked by Wall St. Rank hold AEON.WS as of Q1 2023.

  • Citadel Advisors reported no remaining AEON Biopharma Inc position as of Q1 2023 after selling out during the quarter.
  • Citadel Advisors sold 59,281 AEON Biopharma Inc shares in Q1 2023, an estimated $2.7K.
  • Citadel Advisors first reported a position in AEON Biopharma Inc in Q2 2021 and held it in 7 quarters.
  • Citadel Advisors's AEON Biopharma Inc position peaked at $200K in Q2 2021.
  • 49 funds tracked by Wall St. Rank held AEON Biopharma Inc as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.